BioNTech SE

BioNTech SE is a German biotechnology company focused on the development and commercialization of immunotherapies. Its most well-known product is BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus (COVID-19). Beyond infectious diseases, BioNTech has a robust oncology pipeline. Key oncology candidates include Gotistobart (Phase III for metastatic non-small cell lung cancer), Pumitamig (Phase III for small cell lung cancer and triple-negative breast cancer), and Trastuzumab pamirtecan (Phase III for metastatic breast cancer). The company also has drugs in Phase II trials such as BNT116 for advanced non-small cell lung cancer and Autogene cevumeran for advanced colorectal cancer. Additionally, BioNTech is developing vaccines for mpox (BNT166, Phase II) and infectious disease drugs for tuberculosis, malaria, and influenza.

BioNTech SE is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BNTNX. Its shares trade in US Dollars (USD). The company is headquartered in Mainz, Germany, but its primary stock listing is on a US exchange, which allows international investors to trade its shares in the US market.

BioNTech SE operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use living organisms or their components to develop products, often for medical applications. BioNTech focuses on immunotherapies, which harness the immune system to fight diseases, including cancer and infectious diseases. Its work in mRNA technology for vaccines and oncology treatments places it at the forefront of modern biotech innovation.

BioNTech SE is headquartered in Mainz, Germany, and was incorporated in 2008. While based in Germany, the company serves global markets, particularly through its COVID-19 vaccine BNT162, which has been distributed worldwide. Its oncology pipeline targets cancers prevalent in multiple regions, including non-small cell lung cancer, breast cancer, and colorectal cancer. The company also develops vaccines for infectious diseases like mpox, tuberculosis, and malaria, addressing health challenges in various geographies.

BioNTech SE generates revenue primarily through the commercialization of its immunotherapies. Its most significant revenue driver has been the BNT162 mRNA vaccine for COVID-19, which was developed in collaboration with Pfizer and has been sold globally. In addition, the company is advancing a pipeline of oncology drugs in late-stage clinical trials, such as Gotistobart and Pumitamig, which could become future revenue sources upon regulatory approval. BioNTech also develops vaccines for other infectious diseases, including mpox, tuberculosis, and malaria, which may contribute to revenue if they reach the market. The company's business model relies on research and development, partnerships, and eventual product sales.